CTOs on the Move

Zentalis

www.zentalis.com

 
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.zentalis.com
  • 530 Seventh Avenue Suite 2201
    New York, NY USA 10018
  • Phone: 212.433.3791

Executives

Name Title Contact Details
Kea Lingo
Senior Vice President, Chief Information Officer Profile

Funding

Zentalis raised $85M on 12/09/2019
Zentalis raised $172.9M on 07/01/2021

Similar Companies

Puerto Rico Labor and Human Resources

Puerto Rico Labor and Human Resources is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BGI Americas Corporation

BGI Americas Corporation is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GeneGo bioinformatics software

GeneGo bioinformatics software is a Saint Joseph, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

XOMA

XOMA is a late-stage biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company has built an expertise in allosteric modulation and has applied that expertise to expand the therapeutic potential of monoclonal antibodies.  The first compound from XOMA’s allosteric modulating antibody program is gevokizumab, an IL-1 beta modulating antibody.  XOMA has partnered with SERVIER, a global pharmaceutical company based in France, to develop and commercialize gevokizumab for the global market, and the companies are conducting a global Phase 3 program in people with Behçet’s disease uveitis and non-infectious uveitis. Each company also has a proof-of-concept (POC) clinical program in place to identify other IL-1 mediated diseases that could be treated with gevokizumab.  One of these POC studies led XOMA to select its next Phase 3 indication, pyoderma gangrenosum, a rare ulcerative skin disease. XOMA`s scientific research also produced the XMet program, which consists of three classes of preclinical allosteric modulating antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could have a major impact on the treatment of diabetes.  XOMA will retain the compound that has potential to treat several rare insulin dysfunction-related diseases and to out-license the compounds that could address the diabetes markets. 

Ikena Oncology

Ikena Oncology is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients.